Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesGeoVax Labs Inc

GeoVax Labs Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.1579 USD -0.00 ( 0.06%)
Last update at 2026-11-06T21:24:00Z
VOLUME
336042
Market Cap
3.81M

Momentum Score

…

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.14
Low
0.16
High
52 Week Price Range
0.41
Low
17.50
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

GeoVax Labs Inc is a clinical-stage biotech developing vaccines using an MVA‑VLP (modified vaccinia Ankara virus‑like particle) platform to elicit immune responses against infectious diseases and cancer. Long-term growth drivers include clinical program advancement, potential licensing or partnerships, and broader platform adoption that could attract public or private funding and support multiple indications; investors may find the company appealing for its platform-based pipeline leverage.
Principal risks are early-stage development with no predictable commercial revenue, dependence on successful trials and regulatory approvals, financing dilution risk, and competition from larger vaccine developers.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.16
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-15.05M
Debt / Equity
0.22
ROE
-891.59%
Net Debt
-2242571.00M
ROCE
-0.00%
Diluted EPS TTM
-5.47

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -21.46M -24.99M -25.97M -14.02M -18.57M
Net income -21.46M -24.99M -25.97M -14.01M -18.53M
Selling general administrative 6.01M 5.39M 6.02M 4.99M 3.58M
Selling and marketing expenses - 5385248.61M 0.07M - -
Gross profit 2.49M 3.86M -20.72M 0.08M 0.39M
Reconciled depreciation 0.07M 0.10M 0.07M 0.06M 0.04M
Ebit - -24.97M -26.74M -14.09M -18.78M
Ebitda -21.64M -24.88M -26.67M -14.03M -18.75M
Depreciation and amortization - 0.10M 0.07M 0.06M 0.04M
Operating income -21.64M -25.14M -26.74M -14.03M -18.75M
Other operating expenses 24.13M 29.10M 26.74M 14.11M 19.13M
Interest expense 0.00M 0.02M 0.00M -0.06M 0.00M
Interest income 0.17M 0.17M 0.68M 0.01M 0.00M
Net interest income 0.17M 0.15M 0.68M 0.01M 0.00M
Income tax expense - - 0.00M -0.01M -0.04M
Total revenue 2.49M 3.95M 0.00M 0.08M 0.39M
Total operating expenses 24.13M 29.00M 6.02M 14.11M 19.13M
Cost of revenue - 0.10M 20.72M - -
Total other income expense net 0.17M 0.15M 0.78M 0.01M 0.18M
Net income from continuing ops -21.46M -24.99M -23.76M -14.02M -18.57M
Net income applicable to common shares - - - -14.02M -18.57M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 6341868.00M 8.16M 9.28M 31.35M 11.80M
Intangible assets 0.05M 0.06M - - -
Other current assets 2228910.00M 2427942.00M 1.43M 1.33M 0.20M
Total liab 2516736.00M 3.11M 3.52M 4.75M 7.43M
Total stockholder equity 3825132.00M 5.05M 5.76M 26.60M 4.36M
Other current liab 1673565.21M 1.26M 0.72M 3.00M 3.38M
Common stock 0.00M 0.01M 0.00M 0.03M 0.01M
Capital stock 0.00M 0.01M 0.00M 0.03M 0.01M
Retained earnings -150820852.00M -129356081.00M -104.36M -78.40M -64.38M
Other liab - - - - 2.00M
Other assets - - - 2.17M 0.01M
Cash 3085741.00M 5.51M 6.45M 27.61M 11.42M
Total current liabilities 1936701.00M 3.11M 3.52M 4.75M 5.44M
Net debt -2242571.00M -5.51M -6.45M -27.61M -11.42M
Short term debt 263135.00M - - - -
Short long term debt total 843170.00M - - - -
Other stockholder equity 154646138.64M 134404616.00M 110.13M 104.97M 68.73M
Property plant equipment - - - 0.23M 0.16M
Total current assets 5314651.00M 7.93M 7.89M 28.94M 11.63M
Net tangible assets - - - 26.60M 4.36M
Short term investments - 5506935.49M - - -
Net receivables - 0.66M - - 0.05M
Inventory - - - - -0.05M
Accounts payable 0.79M 1.85M 2.80M 1.75M 2.06M
Accumulated other comprehensive income - - 0.00M - -
Non currrent assets other 86946.95M 0.01M 1.19M 2.17M 0.01M
Non current assets total 1027217.00M 0.22M 1.40M 2.41M 0.17M
Capital lease obligations 0.84M 0.00M - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.02M -0.03M -0.13M -0.05M
Change to liabilities - - - -2.69M 6.81M
Total cashflows from investing activities -27612.00M -0.02M -0.05M -0.13M -0.05M
Net borrowings 0.00M -0.01M 0.00M - -0.03M
Total cash from financing activities 19080381.00M 23.75M 4.06M 35.35M 12.78M
Change to operating activities - - - -3.33M -0.02M
Net income -21464771.00M -24.99M -25.97M -14.02M -18.57M
Change in cash -2421200.00M -0.95M -21.16M 16.19M 1.54M
Begin period cash flow 5506941.00M 6.45M 27.61M 11.42M 9.88M
End period cash flow 3085741.00M 5.51M 6.45M 27.61M 11.42M
Total cash from operating activities -21473969.00M -24.68M -25.17M -19.03M -11.20M
Issuance of capital stock 18.92M 21.40M 0.00M 27.73M 9.41M
Depreciation 68756.00M 0.10M 0.07M 0.06M 0.04M
Other cashflows from investing activities -27611.97M -20653.00M - - -
Change to account receivables 0.66M -0.66M - 0.05M 0.13M
Sale purchase of stock - - - 0.00M -0.00M
Other cashflows from financing activities 19080361.92M 2.37M 4.06M 7.63M 3.40M
Change to netincome - - - 0.90M 0.41M
Capital expenditures 0.03M 0.02M 0.05M 0.13M 0.05M
Change in working capital -1.19M -0.31M -0.36M -5.97M 6.93M
Stock based compensation 1115154.00M 0.53M 1.07M 0.90M 0.37M
Other non cash items -1193106.81M -25299497.70M -1228013.00M - 0.04M
Free cash flow -21473969.00M -24.70M -25.22M -19.16M -11.24M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
GOVX
GeoVax Labs Inc		 -0.00
0.06%		 0.16 - 9.65 4.44 2.22 3.28 15.26
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

GeoVax Labs Inc

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.

1955 Lake Park Drive, Smyrna, GA, United States, 30080

678 384 7220

https://www.geovax.com

19

Name Title Year Born
Mr. David Alan Dodd Chairman, Pres & CEO 1950
Mr. Mark W. Reynolds CPA, CPA CFO & Corp. Sec. 1962
Dr. Mark J. Newman Ph.D. Chief Scientific Officer 1955
Dr. Harriet Latham Robinson Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board 1938
Dr. Kelly T. McKee Jr., M.D., M.P.H. Chief Medical Officer 1950
Jeffrey Welch Head of Process Devel. & Manufacturing Operations NA
Mr. David Alan Dodd Chairman, President & CEO 1950
Dr. Kelly T. McKee Jr., M.D., M.P.H. Chief Medical Officer 1951
Dr. Harriet Latham Robinson Ph.D. Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board 1938
Mr. Mark W. Reynolds CPA CFO & Corporate Secretary 1962

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…